Yuanmei Yan

Ms. Yuanmei Yan

Department of neurosurgery, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
HZHeyu Zhu
Heyu Zhu
YYYuanmei Yan
Yuanmei Yan
YJYi Jiang
Yi Jiang
XMXian-Fang Meng
Xian-Fang Meng
Aging is an unavoidable biological process that leads to the decline of human function and the reduction in people’s quality of life. Demand for anti-aging medicines has become very urgent. Many studies have shown that ellagic acid (EA), a phenolic compound widely distributed in dicotyledonous plants, has powerful anti-inflammation and antioxidant properties. Moreover, it has been demonstrated that EA can enhance neuronal viability, reduce neuronal defects, and alleviate damage in neurodegenerative diseases such as Alzheimer’s disease, Parkinson’s disease, and cerebral ischemia. This paper reviews the biochemical functions and neuroprotective effects of EA, showing the clinical value of its application.

7 October 2026 in Biomedicines
Verified
Journal Article
Open access
PDF file
LYLu Yang
Lu Yang
YHYuting Huang
Yuting Huang
ALAndong Liu
Andong Liu
YYYuanmei Yan
Yuanmei Yan
BLBo Liu
Bo Liu
XYXianglin Yuan
Xianglin Yuan
Pulmonary fibrosis is a frequent complication of abnormal tissue repair following lung injury by many causes. It can be found in various diseases and clinical conditions, such as idiopathic pulmonary fibrosis, cancer-treatment-induced lung injury, and other occupational, environmental, and autoimmune lung diseases. Though the initiating factors of these conditions are different, they have several biological mechanisms in common during disease progression, such as injury to and abnormal repair of alveolar epithelial and vascular endothelial cells, immune microenvironment remodeling, macrophage reprogramming, persistent activation of fibroblasts, excessive extracellular matrix deposition, and mechanically driven positive feedback loops. Recent single-cell and spatial multi-omics developments have changed the direction of pulmonary fibrosis research to concentrate on individual signaling pathways to obtain a wider perspective of interactions between cell types. These investigations have discovered significant cell populations, such as abnormal basal-like epithelial cells, SPP1+/TREM2+ profibrotic macrophages, and CTHRC1+ pathological fibroblasts. They have also uncovered new processes, including metabolic–epigenetic interactions, endothelial-to-mesenchymal transition, and macrophage-to-myofibroblast transition that give a new understanding to the pathogenesis of diseases. Pirfenidone and nintedanib may slow the progression of lung dysfunction but do not reverse already existing fibrosis. Thus, knowledge of the complicated cellular and molecular processes of pulmonary fibrosis is critical in determining new therapeutic targets and enhancing existing therapies. This review summarizes pathological characteristics, mechanisms and therapeutic breakthroughs with special emphasis on idiopathic pulmonary fibrosis and cancer-therapy-related lung damage and discusses emerging strategies targeting epithelial repair, endothelial barrier activity, macrophage activity, fibroblast activation, and extracellular matrix remodeling.